Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00019695|
Recruitment Status : Terminated
First Posted : March 5, 2007
Last Update Posted : April 22, 2014
RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is more effective with or without alendronate sodium.
PURPOSE: Randomized phase II trial to study the effectiveness of ketoconazole with or without alendronate sodium in treating patients who have metastatic prostate cancer.
|Condition or disease||Intervention/treatment||Phase|
|Stage IV Prostate Cancer Bone Metastases Adenocarcinoma of the Prostate Recurrent Prostate Cancer||Drug: alendronate sodium Drug: ketoconazole||Phase 2|
OBJECTIVES: I. Determine whether there is any evidence that ketoconazole plus alendronate sodium produces acceptable disease responses as compared with ketoconazole alone in patients with androgen-independent metastatic adenocarcinoma of the prostate.
II. Characterize the pharmacokinetics/pharmacodynamics and assess the bone marrow concentrations of both agents.
III. Assess matrix metalloproteinase (MMP) inhibition potential of alendronate sodium by monitoring markers of angiogenesis, MMP breakdown, and changes in hydroxyproline.
PROTOCOL OUTLINE: This is a randomized, open-label study. Patients are randomized to one of two treatment arms.
Arm I: Patients receive a single oral dose of ketoconazole on day 1. Patients begin taking ketoconazole 3 times per day on day 8.
Arm II: Patients receive a single oral dose of alendronate sodium on day 1 and a single oral dose of ketoconazole on day 3. Patients begin taking alendronate sodium once every morning and ketoconazole 3 times per day on day 8.
Treatment continues on both arms in the absence of unacceptable toxicity or disease progression. Patients who experience a clinical complete remission (CR) receive treatment for an additional 60 days beyond documentation of a clinical CR.
Patients are followed every 2 months.
A total of 72 patients (36 per arm) will be accrued for this study within 3 years.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate|
|Study Start Date :||March 1999|
|Actual Study Completion Date :||March 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00019695
|United States, Maryland|
|Bethesda, Maryland, United States, 20892|
|Study Chair:||William D. Figg||National Cancer Institute (NCI)|